Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company
Business live – latest updates
The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and profits as health systems around the world rush to use it to tackle obesity.
Sales of the Danish pharmaceutical company Novo Nordisk’s diabetes and obesity drugs rose from 113bn Danish kroner (£13.2bn) in the nine months to the end of September 2022 to 154bn kroner for the same period in 2023.
About Author
More Stories
Labor loses $1bn from Victoria’s upcoming budget surplus in favour of ‘practical’ cost-of-living relief
Trump says he has a ‘little problem’ with Tim Cook over Apple’s India production
Son Heung-min tells South Korean police he is victim of blackmail attempt